ArticleFrontiers in allergy2026
Integrative skin-blood transcriptomic analysis identifies circulating biomarkers reflecting disease activity in atopic dermatitis.
Article in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atopic dermatitis (AD) is characterized by complex immune dysregulation primarily studied in lesional skin. Identifying circulating molecular signatures that mirror cutaneous inflammation could enable non-invasive disease monitoring. Methods: Transcriptomic data from lesional skin and peripheral blood T lymphocytes of patients with AD were analyzed using differential expression, pathway enrichment, upstream regulator prediction, and protein-protein interaction network modeling. Genes dysregulated in both compartments were prioritized and validated in serum samples from patients with moderate-to-severe AD. Results: Despite limited concordance at the individual gene level, skin and blood shared a common inflammatory regulatory landscape, including activation of Th2- and Th17-related cytokine signaling, together with a consistently prediction of ESR1 inhibition across both compartments. Network analysis identified key hub genes and a neuro-immune signaling module. Among shared molecules, serum S100A8 levels positively correlated with disease severity, while SOCS3 showed a negative association. LCN2 and CTLA4 displayed trends toward correlation. Conclusions: Systemic molecular alterations in AD partially reflect cutaneous inflammation and support circulating S100A8 and SOCS3 as potential biomarkers of disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.